{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:23:28Z","timestamp":1792783408946,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Paratek Pharmaceuticals, Inc.","id":[{"id":"https:\/\/ror.org\/019g7bh20","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"DOI":"10.1007\/s40121-026-01450-0","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:31:58Z","timestamp":1791279118000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Experience with Omadacycline for the Treatment of Diabetic Foot Infections and Acute Osteomyelitis"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6353-2958","authenticated-orcid":false,"given":"Matthew P.","family":"Crotty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronda L.","family":"Akins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie S.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nebu T.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward A.","family":"Dominguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,6]]},"reference":[{"key":"1450_CR1","unstructured":"National Center for Health S. Health, United States. Health, United States, 2016: with chartbook on long-term trends in health. Hyattsville (MD): National Center for Health Statistics (US); 2017."},{"issue":"5","key":"1450_CR2","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.2337\/diacare.27.5.1047","volume":"27","author":"S Wild","year":"2000","unstructured":"Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2000;27(5):1047\u201353.","journal-title":"Diabetes Care"},{"issue":"2","key":"1450_CR3","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1001\/jama.293.2.217","volume":"293","author":"N Singh","year":"2005","unstructured":"Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes. Jama. 2005;293(2):217\u201328.","journal-title":"Jama."},{"issue":"1","key":"1450_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1177\/1534734606297245","volume":"6","author":"L Prompers","year":"2007","unstructured":"Prompers L, Huijberts M, Apelqvist J, Jude E, Piaggesi A, Bakker K, et al. Optimal organization of health care in diabetic foot disease: introduction to the Eurodiale study. Int J Low Extrem Wounds. 2007;6(1):11\u20137.","journal-title":"Int J Low Extrem Wounds"},{"key":"1450_CR5","doi-asserted-by":"publisher","first-page":"947","DOI":"10.2147\/DMSO.S181198","volume":"12","author":"JL L\u00e1zaro Mart\u00ednez","year":"2019","unstructured":"L\u00e1zaro Mart\u00ednez JL, Garc\u00eda \u00c1lvarez Y, Tard\u00e1guila-Garc\u00eda A, Garc\u00eda Morales E. Optimal management of diabetic foot osteomyelitis: challenges and solutions. Diabetes Metab Syndr Obes. 2019;12:947\u201359.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"10","key":"1450_CR6","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz382","volume":"6","author":"MJ Johnson","year":"2019","unstructured":"Johnson MJ, Shumway N, Bivins M, Bessesen MT. Outcomes of limb-sparing surgery for osteomyelitis in the diabetic foot: importance of the histopathologic margin. Open Forum Infect Dis. 2019;6(10):ofz382.","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"1450_CR7","doi-asserted-by":"publisher","first-page":"651","DOI":"10.2337\/dc13-2176","volume":"37","author":"JB Rice","year":"2014","unstructured":"Rice JB, Desai U, Cummings AK, Birnbaum HG, Skornicki M, Parsons NB. Burden of diabetic foot ulcers for Medicare and private insurers. Diabetes Care. 2014;37(3):651\u20138.","journal-title":"Diabetes Care"},{"issue":"1","key":"1450_CR8","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1177\/2042018817744513","volume":"9","author":"A Raghav","year":"2018","unstructured":"Raghav A, Khan ZA, Labala RK, Ahmad J, Noor S, Mishra BK. Financial burden of diabetic foot ulcers to world: a progressive topic to discuss always. Ther Adv Endocrinol Metab. 2018;9(1):29\u201331.","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"9","key":"1450_CR9","doi-asserted-by":"publisher","first-page":"2819","DOI":"10.1128\/JCM.00551-07","volume":"45","author":"DM Citron","year":"2007","unstructured":"Citron DM, Goldstein EJ, Merriam CV, Lipsky BA, Abramson MA. Bacteriology of moderate-to-severe diabetic foot infections and in vitro activity of antimicrobial agents. J Clin Microbiol. 2007;45(9):2819\u201328.","journal-title":"J Clin Microbiol"},{"key":"1450_CR10","doi-asserted-by":"crossref","unstructured":"Henig O, Pogue JM, Cha R, Kilgore PE, Hayat U, Ja'ara M, et al. Epidemiology of diabetic foot infection in the metro-detroit area with a focus on independent predictors for pathogens resistant to recommended empiric antimicrobial therapy. Open Forum Infect Dis. 2018;5(11):ofy245.","DOI":"10.1093\/ofid\/ofy245"},{"issue":"11","key":"1450_CR11","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1681\/ASN.2004090740","volume":"16","author":"GM Chertow","year":"2005","unstructured":"Chertow GM, Burdick E, Honour M, Bonventre JV, Bates DW. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol. 2005;16(11):3365\u201370.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"1450_CR12","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1097\/CCM.0000000000002769","volume":"46","author":"MK Luther","year":"2018","unstructured":"Luther MK, Timbrook TT, Caffrey AR, Dosa D, Lodise TP, LaPlante KL. Vancomycin plus piperacillin-tazobactam and acute kidney injury in adults: a systematic review and meta-analysis. Crit Care Med. 2018;46(1):12\u201320.","journal-title":"Crit Care Med"},{"issue":"5","key":"1450_CR13","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1093\/cid\/ciw811","volume":"64","author":"DA Hammond","year":"2017","unstructured":"Hammond DA, Smith MN, Li C, Hayes SM, Lusardi K, Bookstaver PB. Systematic review and meta-analysis of acute kidney injury associated with concomitant vancomycin and piperacillin\/tazobactam. Clin Infect Dis. 2017;64(5):666\u201374.","journal-title":"Clin Infect Dis"},{"issue":"7","key":"1450_CR14","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/cix1085","volume":"66","author":"LC McDonald","year":"2017","unstructured":"McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE, et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2017;66(7):e1\u201348.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"1450_CR15","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1016\/j.cmi.2018.02.013","volume":"24","author":"ML Davis","year":"2018","unstructured":"Davis ML, Sparrow HG, Ikwuagwu JO, Musick WL, Garey KW, Perez KK. Multicentre derivation and validation of a simple predictive index for healthcare-associated Clostridium difficile infection. Clin Microbiol Infect. 2018;24(11):1190\u20134.","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"1450_CR16","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1111\/j.1469-0691.2011.03571.x","volume":"18","author":"SM McGlone","year":"2012","unstructured":"McGlone SM, Bailey RR, Zimmer SM, Popovich MJ, Tian Y, Ufberg P, et al. The economic burden of Clostridium difficile. Clin Microbiol Infect. 2012;18(3):282\u20139.","journal-title":"Clin Microbiol Infect"},{"issue":"Suppl 1","key":"1450_CR17","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/dmrr.2699","volume":"32","author":"BA Lipsky","year":"2016","unstructured":"Lipsky BA, Arag\u00f3n-S\u00e1nchez J, Diggle M, Embil J, Kono S, Lavery L, et al. IWGDF guidance on the diagnosis and management of foot infections in persons with diabetes. Diabetes Metab Res Rev. 2016;32(Suppl 1):45\u201374.","journal-title":"Diabetes Metab Res Rev"},{"issue":"5","key":"1450_CR18","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1128\/AAC.02176-12","volume":"57","author":"KA Brown","year":"2013","unstructured":"Brown KA, Khanafer N, Daneman N, Fisman DN. Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection. Antimicrob Agents Chemother. 2013;57(5):2326\u201332.","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 1","key":"1450_CR19","doi-asserted-by":"publisher","first-page":"S40","DOI":"10.1093\/cid\/ciz398","volume":"69","author":"S Opal","year":"2019","unstructured":"Opal S, File TM, van der Poll T, Tzanis E, Chitra S, McGovern PC. An integrated safety summary of omadacycline, a novel aminomethylcycline antibiotic. Clin Infect Dis. 2019;69(Suppl 1):S40-s7.","journal-title":"Clin Infect Dis"},{"key":"1450_CR20","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01581-18","author":"IB Moura","year":"2019","unstructured":"Moura IB, Buckley AM, Ewin D, Shearman S, Clark E, Wilcox MH, et al. Omadacycline gut microbiome exposure does not induce Clostridium difficile proliferation or toxin production in a model that simulates the proximal, medial, and distal human colon. Antimicrob Agents Chemother. 2019. https:\/\/doi.org\/10.1128\/AAC.01581-18.","journal-title":"Antimicrob Agents Chemother"},{"key":"1450_CR21","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02411-16","author":"MA Pfaller","year":"2017","unstructured":"Pfaller MA, Rhomberg PR, Huband MD, Flamm RK. Activities of omadacycline and comparator agents against Staphylococcus aureus isolates from a surveillance program conducted in North America and Europe. Antimicrob Agents Chemother. 2017. https:\/\/doi.org\/10.1128\/AAC.02411-16.","journal-title":"Antimicrob Agents Chemother"},{"key":"1450_CR22","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02327-17","author":"MA Pfaller","year":"2016","unstructured":"Pfaller MA, Huband MD, Shortridge D, Flamm RK. Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe as part of the 2016 SENTRY antimicrobial surveillance program. Antimicrob Agents Chemother. 2016. https:\/\/doi.org\/10.1128\/AAC.02327-17.","journal-title":"Antimicrob Agents Chemother"},{"key":"1450_CR23","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00047-18","author":"L Stapert","year":"2018","unstructured":"Stapert L, Wolfe C, Shinabarger D, Marra A, Pillar C. In vitro activities of omadacycline and comparators against anaerobic bacteria. Antimicrob Agents Chemother. 2018. https:\/\/doi.org\/10.1128\/AAC.00047-18.","journal-title":"Antimicrob Agents Chemother"},{"key":"1450_CR24","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01784-16","author":"W Lin","year":"2017","unstructured":"Lin W, Flarakos J, Du Y, Hu W, He H, Mangold J, et al. Pharmacokinetics, distribution, metabolism, and excretion of omadacycline following a single intravenous or oral dose of 14C-omadacycline in rats. Antimicrob Agents Chemother. 2017. https:\/\/doi.org\/10.1128\/AAC.01784-16.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"1450_CR25","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01703-21","volume":"66","author":"MJ Karau","year":"2022","unstructured":"Karau MJ, Schmidt-Malan SM, Cunningham SA, Mandrekar JN, Pritt BS, Keepers TR, et al. Activity of omadacycline in rat methicillin-resistant Staphylococcus aureus osteomyelitis. Antimicrob Agents Chemother. 2022;66(1):e0170321.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"1450_CR26","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.2337\/dc12-2712","volume":"36","author":"DK Wukich","year":"2013","unstructured":"Wukich DK, Armstrong DG, Attinger CE, Boulton AJ, Burns PR, Frykberg RG, et al. Inpatient management of diabetic foot disorders: a clinical guide. Diabetes Care. 2013;36(9):2862\u201371.","journal-title":"Diabetes Care"},{"issue":"1","key":"1450_CR27","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1186\/s12879-023-08212-0","volume":"23","author":"F Lin","year":"2023","unstructured":"Lin F, He R, Yu B, Deng B, Ling B, Yuan M. Omadacycline for treatment of acute bacterial infections: a meta-analysis of phase II\/III trials. BMC Infect Dis. 2023;23(1):232.","journal-title":"BMC Infect Dis."},{"key":"1450_CR28","doi-asserted-by":"crossref","unstructured":"Kang AY, Garcia Delgado G, Phan Tran D, Flores EA, Romo-Kozan V, Payan I, et al. P-67. Safety of omadacycline versus standard-of-care oral antibiotic treatment for bone and joint infections: interim results from an open-label, non-inferiority, randomized controlled trial. Open Forum Infect Dis. 12: \u00a9 The Author(s) 2025. Published by Oxford University Press on behalf of Infectious Diseases Society of America.; 2025.","DOI":"10.1093\/ofid\/ofae631.274"},{"issue":"2","key":"1450_CR29","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1177\/10600280221089007","volume":"57","author":"KW Garey","year":"2023","unstructured":"Garey KW, Rose W, Gunter K, Serio AW, Wilcox MH. Omadacycline and Clostridioides difficile: a systematic review of preclinical and clinical evidence. Ann Pharmacother. 2023;57(2):184\u201392.","journal-title":"Ann Pharmacother"},{"issue":"8","key":"1450_CR30","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1002\/phar.1799","volume":"36","author":"L Means","year":"2016","unstructured":"Means L, Bleasdale S, Sikka M, Gross AE. Predictors of hospital readmission in patients receiving outpatient parenteral antimicrobial therapy. Pharmacotherapy. 2016;36(8):934\u20139.","journal-title":"Pharmacotherapy"},{"issue":"1","key":"1450_CR31","doi-asserted-by":"publisher","DOI":"10.1017\/ash.2022.330","volume":"3","author":"G Agnihotri","year":"2023","unstructured":"Agnihotri G, Gross AE, Seok M, Yen CY, Khan F, Ebbitt LM, et al. Decreased hospital readmissions after programmatic strengthening of an outpatient parenteral antimicrobial therapy (OPAT) program. Antimicrob Steward Healthc Epidemiol. 2023;3(1):e33.","journal-title":"Antimicrob Steward Healthc Epidemiol."},{"issue":"Suppl 1","key":"1450_CR32","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1002\/dmrr.2739","volume":"32","author":"BA Lipsky","year":"2016","unstructured":"Lipsky BA. Diabetic foot infections: current treatment and delaying the \u201cpost-antibiotic era.\u201d Diabetes Metab Res Rev. 2016;32(Suppl 1):246\u201353.","journal-title":"Diabetes Metab Res Rev"},{"key":"1450_CR33","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.jgar.2025.04.027","volume":"43","author":"MD Huband","year":"2015","unstructured":"Huband MD, Rhomberg PR, Fedler KA, Blankers C, Anastasiou D, Serio AW, et al. In vitro activity of omadacycline against bacterial isolates from bone\/joint infections and rare pathogens in the SENTRY antimicrobial surveillance program (2015-2023). J Glob Antimicrob Resist. 2015;43:271\u201384.","journal-title":"J Glob Antimicrob Resist"},{"key":"1450_CR34","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02488-19","author":"MA Pfaller","year":"2016","unstructured":"Pfaller MA, Huband MD, Shortridge D, Flamm RK. Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: report from the SENTRY antimicrobial surveillance program, 2016 to 2018. Antimicrob Agents Chemother. 2016. https:\/\/doi.org\/10.1128\/AAC.02488-19.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"1450_CR35","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1089\/mdr.2019.0423","volume":"27","author":"A Iregui","year":"2021","unstructured":"Iregui A, Landman D, Quale J. Activity of omadacycline and other tetracyclines against contemporary Gram-negative pathogens from New York City hospitals. Microb Drug Resist. 2021;27(2):190\u20135.","journal-title":"Microb Drug Resist"},{"issue":"1","key":"1450_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2025.107499","volume":"66","author":"Y Chen","year":"2025","unstructured":"Chen Y, Hong Y, Wang X, Cheng X, Zhu F, Wang H, et al. Profiling of omadacycline resistance in clinical MRSA: a nationwide genomic survey and in vitro evolutionary analysis. Int J Antimicrob Agents. 2025;66(1):107499.","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"1450_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-021-06516-7","volume":"21","author":"KE Macdonald","year":"2021","unstructured":"Macdonald KE, Boeckh S, Stacey HJ, Jones JD. The microbiology of diabetic foot infections: a meta-analysis. BMC Infect Dis. 2021;21(1):770.","journal-title":"BMC Infect Dis"},{"issue":"5","key":"1450_CR38","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1093\/jac\/dkac055","volume":"77","author":"CM Gill","year":"2022","unstructured":"Gill CM, Fratoni AJ, Shepard AK, Kuti JL, Nicolau DP. Omadacycline pharmacokinetics and soft-tissue penetration in diabetic patients with wound infections and healthy volunteers using in vivo microdialysis. J Antimicrob Chemother. 2022;77(5):1372\u20138.","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"1450_CR39","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac407","volume":"9","author":"DH Truong","year":"2022","unstructured":"Truong DH, Bedimo R, Malone M, Wukich DK, Oz OK, Killeen AL, et al. Meta-analysis: outcomes of surgical and medical management of diabetic foot osteomyelitis. Open Forum Infect Dis. 2022;9(9):ofac407.","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"1450_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-024-09097-3","volume":"24","author":"W Liang","year":"2024","unstructured":"Liang W, Yin H, Chen H, Xu J, Cai Y. Efficacy and safety of omadacycline for treating complicated skin and soft tissue infections: a meta-analysis of randomized controlled trials. BMC Infect Dis. 2024;24(1):219.","journal-title":"BMC Infect Dis"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01450-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-026-01450-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01450-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:32:00Z","timestamp":1791279120000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-026-01450-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,6]]},"references-count":40,"alternative-id":["1450"],"URL":"https:\/\/doi.org\/10.1007\/s40121-026-01450-0","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,6]]},"assertion":[{"value":"26 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This research was supported by an investigator initiated research grant from Paratek Pharmaceuticals, Inc. Matthew P. Crotty, Ronda L. Akins, Julie S. Alexander, Nebu T. Alexander, Edward A. Dominguez, have nothing else to disclose.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written consent was obtained for all prospectively enrolled patients. The study design was approved by the local institutional review board (protocol 014.PHA.2020.A), and registered on ClinicalTrials.gov (NCT04714411). The study was conducted in accordance to the International Conference on Harmonisation Guidelines for Good Clinical Practice and with the Helsinki Declaration of 1964 and its later amendments.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}